Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Revenue increases 8% to $28.4 million in the year ending December 31 from $26.3 million a year prior. In addition, expects to report an adjusted earnings before interest, tax, depreciation and amortisation above expectations. Notes this will mark the second full year of profitability for Tissue Regenix and the fourth year of above-market growth.

Further, plans to sell the not-for-profit German joint venture, GBM-V. Explains the market dynamics of this joint venture have historically reduced the growth rate of the company and reduced its profit margins. The company’s review of strategic options is continuing.

Current stock price: 58.16 pence

12-month change: down 2.3%

Copyright 2025 Alliance News Ltd. All Rights Reserved.